Pathology Department, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France.
Hepatology. 2013 Sep;58(3):983-94. doi: 10.1002/hep.26433. Epub 2013 Jul 30.
Microvascular invasion (MiVI) is a major risk factor in postoperative tumor recurrence and mortality in hepatocellular carcinoma (HCC). Unfortunately, this histological feature is usually missed by liver biopsy because of limited sampling, and MiVI is commonly detected only after surgery and examination of the full resected specimen. To date, there exists no reliable tool for identifying MiVI prior to surgical procedures. This study aimed to compare the proteome of HCC with and without MiVI in order to identify surrogate biomarkers of MiVI. A training cohort comprising surgically resected primary HCC with MiVI (n = 30) and without MiVI (n = 26) was subjected to matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS). Comparative analysis of acquired mass spectra of the two groups yielded 30 differential protein peaks, among which 28 were more strongly expressed in HCC with MiVI. Among these, two peaks were identified as N-term acetylated histone H4 dimethylated at lysine (K) 20, and N-term acetylated histone H4 dimethylated at K20 and acetylated at K16. Both peaks were validated in the training cohort and in an independent validation cohort (n = 23) by immunohistochemistry and western blot.
These results demonstrate the potential of MALDI IMS for uncovering new relevant biomarkers of MiVI in HCC, and highlight the role of epigenetic modifications in the prognosis of HCC. Preoperative detection of modified forms of histone H4 expression in tumor biopsies would be helpful in management of patients with HCC.
微血管侵犯(MiVI)是肝细胞癌(HCC)术后肿瘤复发和死亡的主要危险因素。不幸的是,由于采样有限,肝活检通常会错过这种组织学特征,并且 MiVI 通常仅在手术后和对完整切除标本进行检查时才被发现。迄今为止,尚无可靠的工具可用于在手术前识别 MiVI。本研究旨在比较有和没有 MiVI 的 HCC 的蛋白质组,以鉴定 MiVI 的替代生物标志物。一个训练队列由有 MiVI(n=30)和没有 MiVI(n=26)的手术切除原发性 HCC 组成,接受基质辅助激光解吸电离成像质谱(MALDI IMS)分析。对两组采集的质谱进行比较分析,得出 30 个差异蛋白峰,其中 28 个在有 MiVI 的 HCC 中表达更强。其中两个峰被鉴定为 N 端乙酰化组蛋白 H4 赖氨酸(K)20 二甲基化,以及 N 端乙酰化组蛋白 H4 赖氨酸(K)20 二甲基化和 K16 乙酰化。通过免疫组织化学和 Western blot 在训练队列和独立验证队列(n=23)中验证了这两个峰。
这些结果表明 MALDI IMS 具有揭示 HCC 中 MiVI 新的相关生物标志物的潜力,并强调了表观遗传修饰在 HCC 预后中的作用。在肿瘤活检中检测组蛋白 H4 表达的修饰形式有助于 HCC 患者的管理。